To date, several biomarkers have already been associated with RA diagnosis and prognosis, such as CRP, ESR, autoantibodies such as anti-citrinullinated peptide antibody, and TNF levels [38–40], although these markers have not been reliable predictors of clinical responses to bDMARDs [41]. This evidence concerns the gene TNF and rheumatoid arthritis.